23/01/2025
Recent research has highlighted the potential of menadione sodium bisulfite (MSB), a synthetic precursor to vitamin K, in targeting cancer cells. A study published in Science demonstrated that MSB induces oxidative cell death in prostate cancer cells by depleting a lipid called phosphatidylinositol 3-phosphate, which is essential for cancer cell survival.
This finding suggests that MSB could be a promising therapeutic agent against certain cancers. However, it's important to note that while these results are encouraging, further research and clinical trials are necessary to fully understand the efficacy and safety of MSB in cancer treatment.
As with any of our posts about cancer treatment, we should be collectively using our resources to end to production of incredible amounts of carcinogens and look to prevent instead of always having to treat.
